William Blair Sticks to Their Buy Rating for Biogen (BIIB)

William Blair analyst Matt Phipps reiterated a Buy rating on Biogen (BIIB – Research Report) on June 15. The company's shares closed last Friday at $388.44. According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Autolus Therapeutics. Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $428.09, which is a 10.6% upside from current levels. In a report issued on June 3, Jefferies also assigned a Buy rating to the stock with a $450.00 price target. See today’s analyst top recommended stocks >> The company has a one-year high of $468.55 and a one-year low of $223.25. Currently, Biogen has an average volume of 1.7M. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The post William Blair Sticks to Their Buy Rating for Biogen (BIIB) appeared first on TipRanks Financial Blog.

William Blair analyst Matt Phipps reiterated a Buy rating on Biogen (BIIB – Research Report) on June 15. The company's shares closed last Friday at $388.44.

According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Autolus Therapeutics.

Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $428.09, which is a 10.6% upside from current levels. In a report issued on June 3, Jefferies also assigned a Buy rating to the stock with a $450.00 price target.

The company has a one-year high of $468.55 and a one-year low of $223.25. Currently, Biogen has an average volume of 1.7M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.

The post William Blair Sticks to Their Buy Rating for Biogen (BIIB) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

William Blair Keeps a Buy Rating on Incyte (INCY)

William Blair analyst Matt Phipps reiterated a Buy rating on Incyte (INCY – Research Report) on June 14. The company's shares closed last Friday at $83.96. According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Autolus Therapeutics. Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $106.83. See today’s analyst top recommended stocks >> Based on Incyte's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $605 million and net profit of $53.54 million. In comparison, last year the company earned revenue of $569 million and had a GAAP net loss of $721 million. Based on the recent corporate insider activity of 118 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INCY in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. The post William Blair Keeps a Buy Rating on Incyte (INCY) appeared first on TipRanks Financial Blog.

William Blair analyst Matt Phipps reiterated a Buy rating on Incyte (INCY – Research Report) on June 14. The company's shares closed last Friday at $83.96.

According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Autolus Therapeutics.

Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $106.83.

Based on Incyte's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $605 million and net profit of $53.54 million. In comparison, last year the company earned revenue of $569 million and had a GAAP net loss of $721 million.

Based on the recent corporate insider activity of 118 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INCY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

The post William Blair Keeps a Buy Rating on Incyte (INCY) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.